(NYSE: ADCT) Adc Therapeutics Sa's forecast annual revenue growth rate of 26.87% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 39.22%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Adc Therapeutics Sa's revenue in 2024 is $69,558,000.On average, 4 Wall Street analysts forecast ADCT's revenue for 2024 to be $6,722,444,414, with the lowest ADCT revenue forecast at $6,183,939,107, and the highest ADCT revenue forecast at $7,144,583,057. On average, 3 Wall Street analysts forecast ADCT's revenue for 2025 to be $8,095,323,461, with the lowest ADCT revenue forecast at $7,894,776,657, and the highest ADCT revenue forecast at $8,385,002,178.
In 2026, ADCT is forecast to generate $12,435,552,443 in revenue, with the lowest revenue forecast at $12,202,819,115 and the highest revenue forecast at $12,668,285,772.